Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Holding CATX?
Track your performance easily
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.20 - $19.05
Previous Close$12.09
Volume221.28K
Average Volume (3M)860.59K
Market Cap
$831.38M
Enterprise Value$526.21M
Total Cash (Recent Filing)$292.87M
Total Debt (Recent Filing)$3.88M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 12, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,430,000
10 Day Avg. Volume525,234
30 Day Avg. Volume860,591
Standard Deviation0.46
R-Squared0.03
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)2.39
Price to Sales (P/S)957.97
Price to Cash Flow (P/CF)-22.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue88.83
Enterprise Value/Gross Profit366.95
Enterprise Value/Ebitda-15.12
Forecast
1Y Price Target
$22.14Price Target Upside79.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Perspective Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataVMT-α-NET is currently being evaluated in a study with initial results from cohorts expected to show a higher confirmed overall response rate compared to Lutathera, indicating potential to supplant the standard of care.
Efficacy And SafetyCATX can advance the radiopharmaceutical landscape with its targeted lead212-based programs, which should generate differentiated efficacy and safety profiles compared to agents utilizing lutetium and actinium.
Manufacturing ExpansionManufacturing sites have now been purchased in/near Somerset (New Jersey), Houston (Texas), and Chicago (Illinois) and are being brought online to support production of assets.
Bears Say
Efficacy ConcernsCohort 2 demonstrated limited anti-tumor activity, with all patients progressing after the first or second cycle of treatment.
Reduced Success ProbabilityThe probability of success for VMT01 in melanoma is adjusted from 35% to 20%, leading to a reduction in the price target.
Safety ConcernsThe kidney exposure is a concern for dose escalating with this molecule, likely part of the decision to explore lower doses for combination purposes.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.20 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 8 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.026.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,427,666 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went up 5.707%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Deerfield Management Company, LP. It holds Perspective Therapeutics’s shares valued at 28M.
---
Perspective Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (79.56% Upside)
$22.14 (79.56% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 19.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 22.4%
Last 30 Days ▲ 22.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
359.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
221.21%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$22.14
▲(79.56% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+113.71%
reiterated a buy rating 15 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +113.71% per trade.
---